AnserBio
Nanoparticle based delivery of p53 protein - addressing the most frequent mutation in cancer. -
Company Overview
Snapshot
Founded in January 2017 by Lana Volokh and Dr. Alex Tendler, AnserBio operates with 1–10 employees. The company has raised $6.45 million across 6 funding rounds from 3 investors.
Business overview
AnserBio, formerly ExoProTher Medical, is a biomedical startup focused on developing a novel approach to cancer treatment. The company's core technology utilizes proprietary cell-derived nanoparticles to deliver healthy p53 protein, aiming to restore the body's natural tumor suppression function. This approach targets the p53-based tumor suppression mechanism, which is mutated in over 60% of cancers, including glioblastoma, colon, bladder, ovarian, and small cell lung cancers. AnserBio operates in the Health Tech & Life Sciences sector, specifically within Pharmaceuticals, and is currently in the preclinical stage.
Strategic signal
In January 2021, AnserBio was featured in an article by Globes, highlighting its innovative approach to fighting cancer from within. This coverage underscores the company's potential to disrupt traditional cancer treatments by focusing on the p53-based tumor suppression mechanism, a critical area for oncology. The signal to investors is the early recognition of AnserBio's novel therapeutic strategy, suggesting a promising trajectory in the highly competitive cancer research and development landscape.
Log in to access full profile ›Company Intelligence Q&A
- What is AnserBio's primary focus in cancer treatment?
- AnserBio focuses on developing a novel approach to cancer treatment by addressing the p53-based tumor suppression mechanism, which is mutated in over 60% of cancers. The company uses proprietary cell-derived nanoparticles to deliver healthy p53 protein and restore natural tumor suppression.
- When was AnserBio founded and by whom?
- AnserBio was founded in January 2017 by Lana Volokh and Dr. Alex Tendler.
- Which investor participated in AnserBio's July 2023 SAFE funding round?
- In July 2023, Peregrine Ventures participated in AnserBio's SAFE funding round, investing $700,000.
- What is the current development stage of AnserBio's cancer treatment?
- AnserBio's cancer treatment is currently in the preclinical stage of development.